NCT06784726 2026-03-13
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
University of Washington
Phase 2 Recruiting
Clinical Trials
7 trialsNCT07463781 2026-03-13
NEURO_CAR-T
Fondazione Italiana Linfomi - ETS
Not yet recruiting
NCT04512716 2026-02-17
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT05800405 2026-02-04
Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma
City of Hope Medical Center
Phase EARLY_PHASE1 Recruiting
NCT04545762 2026-01-14
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
University of California, San Francisco
Phase 1 Recruiting
NCT05852717 2026-01-12
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT03277729 2026-01-05
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Fred Hutchinson Cancer Center
Phase 1/2 Active not recruiting